Literature DB >> 202436

Serum lipids in angiographically assessed coronary atherosclerosis.

M H Frick, G Dahlén, K Berg, M Valle, P Hekali.   

Abstract

Cholesterol, triglycerides, and Lp(a)/pre-beta1 lipoprotein were analyzed in 153 patients typed for liproprotien patterns. Coronary atherosclerosis was determined by selective coronary angiography and graded by a system taking into account proximal, middle and distal segments. Smoking habits, family history and hypertension were also recorded. Normal coronary arteries were encountered in 45, moderate coronary atherosclerosis (less than median score) in 50, and severe changes (greater than median score) in 58 patients. Cholesterol (P less than 0.05), positivity of Lp (a)/pre-beta1 lipoprotein (P less than 0.01), a family history of coronary heart disease (P less than 0.05), and smoking (P less than 0.01) differed between the group of normal arteries and the whole group of luminal obstructions. Serum triglycerides were not associated with coronary atherosclerosis. Cholesterol, positivity of the Lp(a)/pre-beta1 lipoprotein and a family history of coronary heart disease were also associated with the severity of the disease. Smoking was less prevalent in the group with severe changes.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 202436     DOI: 10.1378/chest.73.1.62

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Lipoprotein (a). Heterogeneity and biological relevance.

Authors:  A M Scanu; G M Fless
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

Review 2.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Authors:  Børge G Nordestgaard; Anne Langsted
Journal:  J Lipid Res       Date:  2016-09-27       Impact factor: 5.922

3.  Coronary artery bypass grafting and hyperlipidaemia.

Authors:  G Thompson; R Sapsford
Journal:  Br Heart J       Date:  1985-03

4.  Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia.

Authors:  F Pazzucconi; L Mannucci; L Mussoni; G Gianfranceschi; P Maderna; P Werba; G Franceschini; C R Sirtori; E Tremoli
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

5.  Apolipoprotein E4 polymorphism as risk factor for coronary heart disease among Indian subjects.

Authors:  Tester F Ashavaid; Seema P Todur; Kappiareth G Nair
Journal:  Indian J Clin Biochem       Date:  2002-01

6.  Genetic variation in lipoprotein (a) levels in families enriched for coronary artery disease is determined almost entirely by the apolipoprotein (a) gene locus.

Authors:  C A DeMeester; X Bu; R J Gray; A J Lusis; J I Rotter
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

Review 7.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

Review 8.  Lipoprotein(a) and its role in occlusive vascular disease.

Authors:  M Tennant; J K McGeachie
Journal:  Ann R Coll Surg Engl       Date:  1993-01       Impact factor: 1.891

9.  Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation.

Authors:  D G Jamieson; D C Usher; D J Rader; E Lavi
Journal:  Am J Pathol       Date:  1995-12       Impact factor: 4.307

10.  Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuria.

Authors:  H Kapelrud; H J Bangstad; K Dahl-Jørgensen; K Berg; K F Hanssen
Journal:  BMJ       Date:  1991-09-21
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.